Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.62 |
| ▸ | MMP2 | P08253 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | CA2 | P00918 | 7/20 | 0.43 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15745121 | 0.81 | MMP2 (0.41) | MMP9MMP2CA1CA2CA7 | |
| SCHEMBL6683343 | 0.81 | MMP2 (0.68) | MMP9MMP2MMP13MMP1MMP3 | |
| SCHEMBL12891207 | 0.81 | MMP9 (0.56) | MMP9MMP2CA1CA2CA7 | |
| SCHEMBL12102171 | 0.77 | MMP2 (0.62) | MMP9MMP2CA1CA2MMP13 | |
| SCHEMBL13588725 | 0.74 | MAPT (0.47) | CA1CA2CA7CA14CA12 | |
| SCHEMBL29033737 | 0.73 | MMP9 (0.57) | MMP9MMP2CA2MMP13ADAM17 | |
| SCHEMBL15744895 | 0.72 | MMP9 (0.47) | MMP9MMP2CA1CA2CA7 | |
| SCHEMBL27182979 | 0.72 | MMP13 (0.57) | MMP9MMP2MMP13ADAM17MMP1 | |
| SCHEMBL10419177 | 0.71 | MMP9 (0.55) | MMP9MMP2MMP13ADAM17MMP1 | |
| SCHEMBL10420675 | 0.71 | MMP9 (0.55) | MMP9MMP2MMP13ADAM17MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | MMP9 1/4885MMP2 17/4885CA1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.